SC. Clinical application of PET for the evaluation of brain tumors. J Nucl
Med 1991;32:616-22.
[6] Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C,
Marciano D. Use of thallium SPECT to quantify malignancy grade of
gliomas. J Neurosurg 1989;71:342-6.
[7] Di Chiro G, De La Paz RL, Brooks RA, et al. Glucose utilization
of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron
emission tomography. Neurology 1982;32:1323-9.
[8] Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival
in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22.
[9] Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patient with glioma: A predictor of prognosis. Cancer 1988;62:
1074-8.
[10] Oriuchi N, Tamura M, Shibazake T, et al. Clinical evaluation of
thallium-201 SPECT in supratentorial gliomas: Relationship to histologic
grade, prognosis, and proliferative activities. J Nucl Med 1993;34:2085-9.
[11] Waxman AD, Grode M, Ashok G, Kooba A, Ramanna L.
Intraoperative assessment of brain malignancies using Tl-201 (abstract).
J Nucl Med 1993;34:37P.
[12] Schwartz RB, Carvalho PA, Alexander ME, Loeffler JS,
Folkerth R, Holman BL. Radiation necrosis vs. high-grade recurrent
glioma: Differentiation by using dual-isotope SPECT with 201Tl and
99mTc HMPAO. Am J Neuroradiol 1991;12:1187-92.
[13] O'Tuama LA, Janicek MJ, Barnes PD, et al. 201Tl/99mTcHMPAO SPECT imaging of treated childhood brain tumors. Pediatr
Neurol 1991;7:249-57.
[14] Maria BL, Drane WE, Quisling RG, et al. Value of 201
Thallium SPECT imaging in childhood brain tumors. Pediatr Neurosurg
1994;20:11-8.
[15] Maria BL, Drane WE, Quisling RJ, Hoang KB. Significance of
